https://transhumanist.ru/index.php?action=history&feed=atom&title=LILRB1LILRB1 - История изменений2026-11-08T12:56:15ZИстория изменений этой страницы в викиMediaWiki 1.43.6https://transhumanist.ru/index.php?title=LILRB1&diff=5214&oldid=prevOdysseusBot: Новая страница: «Leukocyte immunoglobulin-like receptor subfamily B member 1 precursor (LIR-1) (Leukocyte immunoglobulin-like receptor 1) (CD85 antigen-like family member J) (Immu...»2021-05-12T13:34:29Z<p>Новая страница: «Leukocyte immunoglobulin-like receptor subfamily B member 1 precursor (LIR-1) (Leukocyte immunoglobulin-like receptor 1) (CD85 antigen-like family member J) (Immu...»</p>
<p><b>Новая страница</b></p><div>Leukocyte immunoglobulin-like receptor subfamily B member 1 precursor (LIR-1) (Leukocyte immunoglobulin-like receptor 1) (CD85 antigen-like family member J) (Immunoglobulin-like transcript 2) (ILT-2) (Monocyte/macrophage immunoglobulin-like receptor 7) (MIR-7) (CD85j antigen) [ILT2] [LIR1] [MIR7]<br />
<br />
==Publications==<br />
<br />
{{medline-entry<br />
|title=Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy.<br />
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/20580616<br />
|abstract=NK cell receptors (NKR) are expressed in subsets of NK and CD8 T cells, lymphocytes involved in multiple sclerosis (MS) pathogenesis. Clinical implications of NKR expression in MS are unknown. Here, we show that the proportions of CD8 T cells displaying [[LILRB1]], an inhibitory NKR expressed at late stages of T cell differentiation, were directly related with age and MS duration, and inversely with the immunomodulatory therapy-dependent increase of CD56(bright) NK cells. Similar associations were found for KIR and CD56 CD8 T cells, whereas no age-related NKR distribution was perceived in controls. Moreover, active MS had lower [[LILRB1]] NK cells, and IFN-β-treated patients exhibited a phenotypic profile related to shorter disease evolution. Progressive accumulation of terminally differentiated T lymphocytes and experienced NK cells in MS, presumably stimulated in response to a persistent challenge and modulated by IFN-β therapy, may support the analysis of NKR distribution as new biomarkers.<br />
|mesh-terms=* Adult<br />
* Aging<br />
* Antibodies<br />
* Antigens, CD<br />
* Biomarkers<br />
* CD56 Antigen<br />
* CD8-Positive T-Lymphocytes<br />
* Cell Count<br />
* Cytomegalovirus Infections<br />
* Female<br />
* Humans<br />
* Interferon-beta<br />
* Killer Cells, Natural<br />
* Leukocyte Immunoglobulin-like Receptor B1<br />
* Leukocytes, Mononuclear<br />
* Lymphocytes<br />
* Male<br />
* Middle Aged<br />
* Multiple Sclerosis<br />
* Multiple Sclerosis, Chronic Progressive<br />
* Multiple Sclerosis, Relapsing-Remitting<br />
* NK Cell Lectin-Like Receptor Subfamily C<br />
* Receptors, Immunologic<br />
* Receptors, KIR<br />
* Receptors, Natural Killer Cell<br />
* Recurrence<br />
* Time Factors<br />
<br />
|full-text-url=https://sci-hub.do/10.1016/j.clim.2010.06.002<br />
}}</div>OdysseusBot